Skip to main content

Table 4 Treatment-related adverse events (TRAEs)

From: Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Treatment-related adverse events n (%)
Any grade ≥grade 2
All TRAEs 31 (53%) 18 (31%)
 Common TRAEs 25 (43%) 10 (17%)
  Anorexia 9 (16%) 3 (5%)
  Malaise 6 (10%) 0
  Nausea 3 (5%) 0
  Upper gastrointestinal hemorrhage 2 (3%) 2 (3%)
  Fever 2 (3%) 0
  Localized edema 2 (3%) 0
  Creatinine increased 2 (3%) 0
  Dysgeusia 2 (3%) 0
  Pruritus 2 (3%) 0
  Nail change 2 (3%) 0
  Anemia 1 (2%) 1 (2%)
  Palpitations 1 (2%) 1 (2%)
  Colonic perforation 1 (2%) 1 (2%)
  Neutrophil count decreased 1 (2%) 1 (2%)
  Dyspnea 1 (2%) 1 (2%)
  Pleural effusion 1 (2%) 1 (2%)
  Eosinophilia 1 (2%) 0
  Constipation 1 (2%) 0
  Platelet count decreased 1 (2%) 0
  Proteinuria 1 (2%) 0
  Cough 1 (2%) 0
 Immune-related adverse events (irAEs) 20 (35%) 10 (17%)
  Liver enzyme elevation 7 (12%) 3 (5%)
  Peripheral sensory neuropathy 4 (7%) 2 (3%)
  Rash maculopapular 4 (7%) 1 (2%)
  Colitis 4 (7%) 0
  Hypothyroidism 2 (3%) 2 (3%)
  Hyperglycemia 1 (2%) 1 (2%)
  Esophagitis 1 (2%) 1 (2%)
  Hypopituitarism 1 (2%) 1 (2%)